Can-Fite BioPharma Ltd.
CANF- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001536196
No open-market purchases or sales by Can-Fite BioPharma Ltd. insiders were filed in the last 90 days; 8 institutions reported holding it in 13F filings for Q2 2026, worth $149.1K in total; no superinvestor holds it.
13F holders, Q1 2023
Institutional positions in Can-Fite BioPharma Ltd. as of Mar 31, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 9
- −2 vs. Q4 2022
- Shares held
- 368.4K
- +325.7K (+761.3%) vs. Q4 2022Converted for a 1-for-10 split
- Total value
- $843.5K
- +$581.3K (+221.7%) vs. Q4 2022
- New holders
- 2
- 1 more added
- Sold out
- 4
- 3 more reduced
Compare with Q4 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting CANF on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 8 | $149.1K |
| Q1 2026 | 14 | $428.6K |
| Q4 2025 | 16 | $78.3K |
| Q3 2025 | 16 | $952.6K |
| Q2 2025 | 16 | $950.1K |
| Q1 2025 | 14 | $193.9K |
| Q4 2024 | 13 | $185.9K |
| Q3 2024 | 12 | $1.52M |
| Q2 2024 | 11 | $1.62M |
| Q1 2024 | 8 | $1.06M |
| Q4 2023 | 9 | $536.4K |
| Q3 2023 | 9 | $179.2K |
| Q2 2023 | 7 | $167.8K |
| Q1 2023 | 9 | $843.5K |
| Q4 2022 | 11 | $262.2K |
| Q3 2022 | 12 | $380.5K |
| Q2 2022 | 12 | $464.7K |
| Q1 2022 | 13 | $472.3K |
| Q4 2021 | 15 | $626.5K |
| Q3 2021 | 12 | $2.43M |
| Q2 2021 | 12 | $1.05M |
| Q1 2021 | 15 | $1.09M |
Institutions, Q1 2023
Shares, value and share of portfolio for each institution holding Can-Fite BioPharma Ltd.; share changes are against Q4 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Armistice Capital, LLC | 330,000 | $755.7K | 0.02% | +330,000 | New |
| Morgan Stanley | 33,407 | $76.5K | 0.00% | +2,940+9.6% | AddedConverted for a 1-for-10 split |
| Fifth Third Bancorp | 3,000 | $6.87K | 0.00% | 00.0% | UnchangedConverted for a 1-for-10 split |
| UBS Group AG | 714 | $1.64K | 0.00% | −157−18.0% | ReducedConverted for a 1-for-10 split |
| National Bank of Canada | 600 | $1.35K | 0.00% | 00.0% | UnchangedConverted for a 1-for-10 split |
| Citigroup Inc | 553 | $1.27K | 0.00% | 00.0% | UnchangedConverted for a 1-for-10 split |
| Federation des caisses Desjardins du Quebec | 53 | $121 | 0.00% | −0−0.6% | ReducedConverted for a 1-for-10 split |
| TD Waterhouse Canada Inc. | 20 | $59 | 0.00% | −0−1.5% | ReducedConverted for a 1-for-10 split |
| JPMorgan Chase & Co | 100 | $0 | 0.00% | +100 | New |
| Susquehanna International Group, LLP | 0 | $0 | 0.00% | −3,274−100.0% | Sold outConverted for a 1-for-10 split |
| Two Sigma Securities, LLC | 0 | $0 | 0.00% | −2,699−100.0% | Sold outConverted for a 1-for-10 split |
| Stifel Financial Corp | 0 | $0 | 0.00% | −1,200−100.0% | Sold outConverted for a 1-for-10 split |
| BNP Paribas Arbitrage, SA | 0 | $0 | 0.00% | −40−100.0% | Sold outConverted for a 1-for-10 split |